Shire (NASDAQ:SHPG) has been given a $222.00 price target by analysts at Cantor Fitzgerald in a report issued on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 40.28% from the company’s previous close.
SHPG has been the topic of a number of other research reports. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. Liberum Capital upgraded Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. ValuEngine upgraded Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Royal Bank of Canada reiterated a “buy” rating and set a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. Finally, FBR & Co reiterated a “buy” rating and set a $201.00 target price on shares of Shire in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $212.18.
Shares of Shire (NASDAQ SHPG) traded down $0.96 during midday trading on Wednesday, hitting $158.25. 1,092,717 shares of the stock were exchanged, compared to its average volume of 1,101,750. The firm has a market cap of $47,510.00, a PE ratio of 29.80, a price-to-earnings-growth ratio of 0.83 and a beta of 1.59. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same period in the previous year, the business earned $3.17 EPS. Shire’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities analysts forecast that Shire will post 15 EPS for the current year.
A number of hedge funds have recently made changes to their positions in SHPG. Whittier Trust Co. lifted its holdings in Shire by 19.1% in the 1st quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 92 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of Shire by 157.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 372 shares during the last quarter. Pinnacle Bank acquired a new stake in shares of Shire in the 1st quarter worth $101,000. Canal Insurance CO acquired a new stake in shares of Shire in the 2nd quarter worth $102,000. Finally, Hartford Financial Management Inc. increased its stake in shares of Shire by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 32 shares during the last quarter. Institutional investors own 20.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Shire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald Analysts” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/03/shire-shpg-given-a-222-00-price-target-by-cantor-fitzgerald-analysts-2.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.